128 related articles for article (PubMed ID: 38518485)
1. A comparison of the clinical and histological appearances after treatment of advanced stage ovarian cancer with PlasmaJet® device.
Natarajan P; Martha Schofield A; Elena Vinturache A; Ruthven S; Lane S; Duncan Macdonald R
Eur J Obstet Gynecol Reprod Biol; 2024 May; 296():311-315. PubMed ID: 38518485
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of the PlasmaJet® Device in advanced stage ovarian carcinoma: a systematic review.
Nieuwenhuyzen-de Boer GM; van der Kooy J; van Beekhuizen HJ
J Ovarian Res; 2019 Jul; 12(1):71. PubMed ID: 31362769
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands.
Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Ewing-Graham PC; Schoots IG; Beltman JJ; Piek JMJ; Baalbergen A; Kooi GS; van Haaften A; van Huisseling H; Haans L; Dorman M; van Beekhuizen HJ
BMC Cancer; 2019 Jan; 19(1):58. PubMed ID: 30642296
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands.
Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Willemsen S; Boere IA; Schoots IG; Piek JMJ; Hofman LN; Beltman JJ; van Driel WJ; Werner HMJ; Baalbergen A; van Haaften-de Jong AMLD; Dorman M; Haans L; Nedelcu I; Ewing-Graham PC; van Beekhuizen HJ
Ann Surg Oncol; 2022 Aug; 29(8):4833-4843. PubMed ID: 35552938
[TBL] [Abstract][Full Text] [Related]
5. The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series.
Nieuwenhuyzen-de Boer GM; van de Berg NJ; Gao XS; Ewing-Graham PC; van Beekhuizen HJ
J Ovarian Res; 2022 Dec; 15(1):140. PubMed ID: 36581854
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
[TBL] [Abstract][Full Text] [Related]
7. Cost Study of the PlasmaJet Surgical Device Versus Conventional Cytoreductive Surgery in Patients With Advanced-Stage Ovarian Cancer.
Nieuwenhuyzen-de Boer GM; Geraerds AJLM; van der Linden MH; van Doorn HC; Polinder S; van Beekhuizen HJ
JCO Clin Cancer Inform; 2022 Sep; 6():e2200076. PubMed ID: 36198130
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
9. Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer.
Panuccio E; Leunen K; Van Nieuwenhuysen E; Neven P; Lambrechts S; Vergote I
Int J Gynecol Cancer; 2016 Oct; 26(8):1521-4. PubMed ID: 27488213
[TBL] [Abstract][Full Text] [Related]
10. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
Cordeiro Vidal G; Babin G; Querleu D; Guyon F
Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
[TBL] [Abstract][Full Text] [Related]
11. The Emerging Role of Neutral Argon Plasma (PlasmaJet) in the Treatment of Advanced Stage Ovarian Cancer: A Systematic Review.
Prodromidou A; Pandraklakis A; Iavazzo C
Surg Innov; 2020 Jun; 27(3):299-306. PubMed ID: 32129144
[No Abstract] [Full Text] [Related]
12. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
13. Robotic surgery in early and advanced ovarian cancer: Case selection for surgical staging and interval debulking surgery.
Van Trappen P; de Cuypere E; Claes N
Eur J Obstet Gynecol Reprod Biol; 2023 Jan; 280():7-11. PubMed ID: 36371963
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
15. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
Hiu S; Bryant A; Gajjar K; Kunonga PT; Naik R
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD007697. PubMed ID: 36041232
[TBL] [Abstract][Full Text] [Related]
16. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Lyons TJ; Goodall RJ; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684686
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD005343. PubMed ID: 33543776
[TBL] [Abstract][Full Text] [Related]
19. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
20. To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.
Kumari A; Thakur M; Saha SC; Suri V; Prasad GRV; Patel FD; Radhika S
J Obstet Gynaecol; 2021 May; 41(4):616-620. PubMed ID: 32811236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
